Answers are grounded in this paper and cite their sources.
Non-small-cell lung cancer (NSCLC) in early stages (I-IIIA) presents an epidermal growth factor receptor (EGFR) gene mutation in 13-17 % of patients in western countries, being more common in Asian populations. Clinical, radiological and molecular characteristics of these patients differ slightly from both those in early-stage NSCLC without EGFR mutation and those in advanced NSCLC with EGFR mutation. Recently, adjuvant treatment with osimertinib, a third-generation inhibitor, has resulted in an improvement in patients with EGFR mutation, representing a change in clinical practice. This review presents the epidemiological aspect as well as clinical, radiological and molecular characteristics of this population. We also review the particularities of adjuvant chemotherapy and immunotherapy as well as the available evidence regarding treatment with EGFR inhibitors in the adjuvant and in the neoadjuvant settings.
No takes yet. Share an insight, caveat, or question.
Tarruella et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: